Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T 1H MRS imaging study

Chronic fatigue syndrome (CFS) is a controversial diagnosis because of the lack of biomarkers for the illness and its symptom overlap with neuropsychiatric, infectious, and rheumatological disorders. We compared lateral ventricular volumes derived from tissue‐segmented T1‐weighted volumetric MRI data and cerebrospinal fluid (CSF) lactate concentrations measured by proton MRS imaging (1H MRSI) in 16 subjects with CFS (modified US Centers for Disease Control and Prevention criteria) with those in 14 patients with generalized anxiety disorder (GAD) and in 15 healthy volunteers, matched group‐wise for age, sex, body mass index, handedness, and IQ. Mean lateral ventricular lactate concentrations measured by 1H MRSI in CFS were increased by 297% compared with those in GAD (P < 0.001) and by 348% compared with those in healthy volunteers (P < 0.001), even after controlling for ventricular volume, which did not differ significantly between the groups. Regression analysis revealed that diagnosis accounted for 43% of the variance in ventricular lactate. CFS is associated with significantly raised concentrations of ventricular lactate, potentially consistent with recent evidence of decreased cortical blood flow, secondary mitochondrial dysfunction, and/or oxidative stress abnormalities in the disorder. Copyright © 2008 John Wiley & Sons, Ltd.

[1]  H. Onoe,et al.  Reduction of serotonin transporters of patients with chronic fatigue syndrome , 2004, Neuroreport.

[2]  D. Bates,et al.  SPECT imaging of the brain: comparison of findings in patients with chronic fatigue syndrome, AIDS dementia complex, and major unipolar depression. , 1994, AJR. American journal of roentgenology.

[3]  A. Rademaker,et al.  A community-based study of chronic fatigue syndrome. , 1999, Archives of internal medicine.

[4]  Joseph A Maldjian,et al.  Brain MRI abnormalities exist in a subset of patients with chronic fatigue syndrome , 1999, Journal of the Neurological Sciences.

[5]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[6]  David C Hoaglin,et al.  Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. , 2003, Archives of internal medicine.

[7]  G. Fricchione.  Generalized Anxiety Disorder , 2004 .

[8]  M. Hamilton.  The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.

[9]  J. DeLuca,et al.  Neuropsychological deficits in patients with chronic fatigue syndrome , 2004, Journal of the International Neuropsychological Society.

[10]  Michael B. First,et al.  The Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II): I. Description. , 1995 .

[11]  G. Zeevalk,et al.  Mitochondrial inhibition and oxidative stress: reciprocating players in neurodegeneration. , 2005, Antioxidants & redox signaling.

[12]  L D Devanur,et al.  Chronic fatigue syndrome. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[13]  B. Grant,et al.  Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions , 2005, Psychological Medicine.

[14]  Cassio Pennachin,et al.  Combinations of single nucleotide polymorphisms in neuroendocrine effector and receptor genes predict chronic fatigue syndrome. , 2006, Pharmacogenomics.

[15]  J. Leigh,et al.  Blood flow and muscle metabolism in chronic fatigue syndrome. , 2003, Clinical science.

[16]  Z. Bhujwalla,et al.  Determination of Absolute Phosphate Metabolite Concentrations in RIF‐1 Tumors in Vivo by 31P‐1H‐2H NMR Spectroscopy Using Water as an Internal Intensity Reference , 1992, Magnetic resonance in medicine.

[17]  J. DeLuca,et al.  Quantitative Assessment of Cerebral Ventricular Volumes in Chronic Fatigue Syndrome , 2001, Applied neuropsychology.

[18]  M. Watson,et al.  Clinical utility of biochemical analysis of cerebrospinal fluid. , 1995, Clinical chemistry.

[19]  P. Grasby,et al.  Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635 , 2005, Biological Psychiatry.

[20]  M. Pall.  Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. , 2000, Medical hypotheses.

[21]  T J Meyer,et al.  Development and validation of the Penn State Worry Questionnaire. , 1990, Behaviour research and therapy.

[22]  F. Shic,et al.  Accumulation of methylsulfonylmethane in the human brain: identification by multinuclear magnetic resonance spectroscopy. , 2001, Toxicology letters.

[23]  J. Frahm,et al.  Cerebral metabolism in man after acute stroke: New observations using localized proton NMR spectroscopy , 1989, Magnetic resonance in medicine.

[24]  N. Larocca,et al.  The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. , 1989, Archives of neurology.

[25]  H. Möller,et al.  Magnetic resonance spectroscopy in patients with MELAS , 2005, Journal of the Neurological Sciences.

[26]  G. Lewis,et al.  Unexplained fatigue syndromes in a multinational primary care sample: specificity of definition and prevalence and distinctiveness from depression and generalized anxiety. , 2003, The American journal of psychiatry.

[27]  E. Shoubridge,et al.  Oxidative phosphorylation defect in the brains of carriers of the tRNAleu(UUR) A3243G mutation in a MELAS pedigree , 2000, Annals of neurology.

[28]  H. Butt,et al.  Free radicals in chronic fatigue syndrome: cause or effect? , 2000, Redox report : communications in free radical research.

[29]  Daniel J Buysse,et al.  The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research , 1989, Psychiatry Research.

[30]  E. Ellis,et al.  Isoprostanes: free radical-generated prostaglandins with constrictor effects on cerebral arterioles. , 1997, Stroke.

[31]  T. Bucciarelli,et al.  Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome , 2003, Neuroscience Letters.

[32]  Gwen Kennedy,et al.  Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. , 2005, Free radical biology & medicine.

[33]  M Freedman,et al.  Assessment of regional cerebral perfusion by 99Tcm-HMPAO SPECT in chronic fatigue syndrome. , 1992, Nuclear medicine communications.

[34]  I. Hickie,et al.  The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. , 1994, Annals of internal medicine.

[35]  K. Abe.  Cerebral lactic acidosis correlates with neurological impairment in MELAS , 2004, Neurology.

[36]  J H Duyn,et al.  Multisection proton MR spectroscopic imaging of the brain. , 1993, Radiology.

[37]  T. Crawford,et al.  Proton MR spectroscopy in the diagnostic evaluation of suspected mitochondrial disease. , 2003, AJNR. American journal of neuroradiology.

[38]  Ian Hickie,et al.  The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study , 1994, Annals of Internal Medicine.

[39]  H. Butt,et al.  Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome , 2000, Redox report : communications in free radical research.

[40]  B. Natelson,et al.  Patients with chronic fatigue syndrome have reduced absolute cortical blood flow , 2006, Clinical physiology and functional imaging.

[41]  Dedra Buchwald,et al.  Chronic fatigue syndrome: a review. , 2003, The American journal of psychiatry.